RSV Vaccine | AREXVY (Respiratory Syncytial Virus Vaccine, …
WEBAREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in people 60 years of age and older. Important Safety Information. You should not receive AREXVY if …
Arexvy - European Medicines Agency (EMA)
WEBArexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older. The use of this vaccine should be in accordance with official recommendations.
About Arexvy (Respiratory Syncytial Virus (RSV) vaccine ... - GSK
WEBJul 10, 2023 · The MHRA has authorised Arexvy for active immunisation for the prevention of LRTD caused by RSV in adults aged 60 years and older. 6 It is also approved in the US and in member states of the European Union and the European Economic Area (EEA)*. The use of this vaccine should be in accordance with official recommendations.
About AREXVY | AREXVY (Respiratory Syncytial Virus Vaccine, …
WEBLearn about AREXVY, the first FDA-approved vaccination to prevent lung and lower airway infection from RSV in people 60 years of age and older.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
FDA approves first RSV vaccine, clearing GSK’s Arexvy for older …
WEBMay 3, 2023 · Trendline. Inside the world of cell therapies. GSK’s shot, called Arexvy, is cleared only for use in adults 60 years or older. The company has not yet disclosed a specific price, but executives have previously indicated they will charge between $60 and $185 a dose, around what vaccines for influenza and shingles cost.
First RSV vaccine for older adults is approved in Europe
WEBApr 28, 2023 · The European Medicines Agency (EMA) has recommended a marketing authorisation for Arexvy, the first vaccine to protect people aged over 60 against respiratory syncytial virus (RSV) infection.1 Arexvy was evaluated under the EMA’s accelerated assessment mechanism for products determined to be of major public health interest.
US FDA approves GSK’s Arexvy, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
First vaccine to protect older adults from respiratory syncytial virus ...
WEBApr 26, 2023 · EMA has recommended a marketing authorisation in the European Union (EU) for Arexvy (recombinant, adjuvanted), the first vaccine for active immunisation to protect adults aged 60 years and older against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV).
WEBWhat is Arexvy and what is it used for? Arexvy is a vaccine for adults 60 years of age and older to protect them against lower respiratory tract disease (LRTD; diseases of the lungs such as bronchitis or pneumonia) caused by respiratory syncytial virus (RSV). Arexvy contains a version of a protein found on the surface of the virus called RSVPreF3.
Skip to content